Key clinical point: Palbociclib plus fulvestrant or exemestane was not superior to capecitabine in hormone receptor–positive, /HER2-negatvie metastatic breast cancer.

Major finding: The trial did not meet coprimary endpoints of superior progression-free survival with palbociclib plus endocrine therapy, regardless of ESR1 status or in ESR1 wild type.

Study details: A randomized, phase 3 trial with two cohorts of 296 and 305 patients.

Disclosures: The study was funded by Pfizer. Dr. Martin disclosed speaker honoraria and consulting fees from Pfizer and others.